2024-09-02 - Analysis Report
## Gilead Sciences, Inc. (GILD) Stock Analysis

**Company Overview:** Gilead Sciences, Inc. is a biopharmaceutical company that develops and commercializes drugs for the treatment of life-threatening diseases, including HIV/AIDS, hepatitis B and C, and cancer.

**1. Performance vs. S&P 500 (VOO)**

* GILD's cumulative return is 14.51%, while the S&P 500 (VOO) has returned 89.66%.
* This results in a **-75.15% deviation**, placing GILD significantly below the market performance.
* The relative deviation of -75.15% indicates that GILD is currently at the **15.83% percentile** of its historical performance range against the S&P 500. 

**2. Recent Price Action**

* **Closing price:** $79.0
* **5-day Moving Average:** $78.19
* **20-day Moving Average:** $75.47
* **60-day Moving Average:** $71.78

GILD is currently trading above its short-term and long-term moving averages, suggesting potential upward momentum.

**3. Technical Indicators**

* **RSI:** 87.42.  The RSI is in overbought territory, indicating the stock may be due for a correction.
* **PPO:** 0.4. The PPO is positive, suggesting potential upward momentum.
* **Delta_Previous_Relative_Divergence:** -5.9. This indicates a recent **short-term downtrend** in relative performance compared to the market.
* **Expected Return:** 21.27%. This suggests a potential **5-year maximum expected return** for current investors.

**4. Recent Earnings & Outlook**

**Recent Earnings:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 1.29 | 6.95 B$ |
| 2024-05-08 | -3.34 | 6.69 B$ |
| 2023-11-07 | 1.75 | 7.05 B$ |
| 2023-08-04 | 0.84 | 6.60 B$ |
| 2024-08-08 | 0.84 | 6.60 B$ |

**Analysis:** The most recent earnings report for 2024-08-08 shows an EPS of 1.29 and revenue of 6.95 B$. This is significantly higher than the previous quarter's results and demonstrates strong growth. However, it's crucial to note that these numbers need to be compared with analyst expectations to get a more accurate picture of the company's performance.

**5. Overall Analysis**

GILD's stock performance has lagged behind the market in the past, with the recent performance suggesting a possible correction due to its overbought RSI. However, the stock's recent earnings results and potential 5-year return suggest a positive outlook. Investors should monitor the stock closely and consider its technical indicators and earnings performance for further analysis. 

**6. Recommendations**

* Monitor GILD's technical indicators closely, especially the RSI and PPO, for potential signs of a correction.
* Analyze earnings reports and compare them to analyst expectations for a more complete understanding of GILD's financial health.
* Consider long-term investment prospects based on the potential 5-year return while acknowledging the potential for short-term market volatility.
